Home > Insider Trading > Filing (0001123292-16-001659)

Filing Details

Accession Number:: 0001123292-16-001659
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-01-29 19:14:12
Reporting Period:: 2016-01-27

Filing Date:: 2016-01-29
Accepted Time:: 2016-01-29 19:14:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175505	Five Prime Therapeutics Inc	FPRX	Pharmaceutical Preparations (2834)	260038620

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1423786	Willard Francis Sarena	C/O Five Prime Therapeutics, Inc. Two Corporate Drive South San Francisco CA 94080	Evp, Gen Counsel & Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-01-27	9,479	$11.14	93,049	No	4	M	Direct
Common Stock	Disposition	2016-01-27	6,895	$35.55	86,154	No	4	S	Direct
Common Stock	Disposition	2016-01-27	2,584	$36.13	83,570	No	4	S	Direct
Common Stock	Acquisiton	2016-01-27	3,791	$10.77	87,361	No	4	M	Direct
Common Stock	Disposition	2016-01-27	3,791	$35.31	83,570	No	4	S	Direct
Common Stock	Acquisiton	2016-01-27	7,449	$7.26	91,019	No	4	M	Direct
Common Stock	Disposition	2016-01-27	7,449	$35.11	83,570	No	4	S	Direct
Common Stock	Acquisiton	2016-01-27	7,768	$5.54	91,338	No	4	M	Direct
Common Stock	Disposition	2016-01-27	7,768	$34.73	83,570	No	4	S	Direct
Common Stock	Acquisiton	2016-01-27	1,513	$8.49	85,083	No	4	M	Direct
Common Stock	Disposition	2016-01-27	1,513	$35.00	83,570	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-01-27	9,479	$0.00	9,479	$11.14
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-01-27	3,791	$0.00	3,791	$10.77
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-01-27	7,449	$0.00	7,449	$7.26
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-01-27	7,768	$0.00	7,768	$5.54
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-01-27	1,513	$0.00	1,513	$8.49

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
25,521	2024-08-21	No	4	M	Direct
3,209	2023-11-04	No	4	M	Direct
12,063	2023-07-18	No	4	M	Direct
24,752	2022-07-15	No	4	M	Direct
926	2021-07-13	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	83,834	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 27, 2015.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.02 to $36.01, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.02 to $36.71, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.85 to $35.76, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.83 to $35.49, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.16 to $35.01, inclusive.
Includes 264 shares granted to the reporting person by the Company pursuant to a company match under the Company's 401(k) plan.
This option began vesting on September 22, 2014, at a rate of 1/48th per month.
The option was vested with respect to one sixteenth of the shares underlying the option on the date of the grant, November 5, 2013. The remainder of the shares underlying the option vest at a rate of 1/48th of the total number of shares underlying the option per month beginning November 19, 2013.
This option began vesting on July 19, 2013, at a rate of 1/48th per month.
This option began vesting on July 12, 2012, at a rate of 1/48th per month.
This option began vesting on July 14, 2011, at a rate of 1/48th per month.